A series of cardiometabolic-related news items has been observed from Madrigal Pharmaceuticals, Beta Bionics, Tidepool/Abbott, Ionis, and Teva. Below, FENIX provides highlights and insights for the respective news items.
On the third day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Insulet, Madrigal, Biomea Fusion, Ionis, and Sana Biotechnology. Separately, a series of CVRM-related news items has been observed:
Three cardiometabolic-related news items have been observed: AstraZeneca initiated a Ph3 baxdrostat + dapagliflozin combination trial in HF (Prevent-HF; view CT.gov record); Ionis (press release; slides) and Teva Pharmaceuticals (press release) hosted their respective Q3 ’24 earnings calls. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Lilly, Regeneron, Alnylam, Antag Therapeutics, Sanofi, Boston Pharmaceuticals, Ionis, Teladoc, Amarin, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items, including initial thoughts on Lilly’s tirzepatide HFpEF results in the context of Novo’s STEP HFpEF and apparent regulatory delay.
A series of cardiometabolic-related news items have been observed from Madrigal, Vertex, Ionis, Esperion, Scholar Rock, and Tandem. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Eccogene, Ionis, and Teladoc. Below, FENIX provides highlights and insights for the respective news items.
On the third day of JPM 2024, FENIX has provided coverage of presentations by other CVRM companies, including Terns, Esperion, Ionis, Amarin, Embecta, and Viatris. Tomorrow is the final day of the JPM 2024 conference with presentations from Lexicon, Mannkind, and Xeris.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Terns, Ionis, Regeneron, and Dario. Below, FENIX provides highlights and insights into the respective news items.
Two cardiometabolic-related news items have been observed: Terns Pharmaceuticals announced positive topline results from its Ph2a DUET trial evaluating TERN-501 as a monotherapy or in combination with TERN-101 for the treatment of NASH (view CT.gov record; press release); and Ionis hosted its Q2 ’23 earnings call (view press release; slides). Below, FENIX provides highlights and insights into the respective news items.
Four cardiometabolic-related news have been observed: Afon Technology is planning to launch a noninvasive blood glucose sensor, called Glucowear, in 2024 (view article); DEKA Research and Development received 510(k) clearance for its DEKA ACE Pump System (view 510(k) decision letter); Novo Nordisk launched Wegovy in Germany without coverage from public health insurance (view article); and Ionis announced the completion of enrollment for its Ph3 CARDIO-TTRansform CVOT of eplontersen in patients with ATTR-CM (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items, including thoughts on who may be interested in commercializing the DEKA pump.